drugset
drugset / Trial / NCT03037606

Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets

NCT03037606 ↗

Phase 4 Completed 48 enrolled Neutec Ar-Ge San ve Tic A.Ş
RandomizedParallel-groupDouble-blindTreatment

Summary

It is planned to compare the efficacy and safety of rabeprazole 50 mg DDR (dual delayed release) capsules versus rabeprazole 20 mg enteric coated tablets administered once daily in patients with Gastroesophageal Reflux Disease (GERD).

Timeline

Start
2017-08-01
Primary completion
2018-12-01
Completion
2018-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Rabeprazole Small molecule 20 mg —
Subject Rabeprazole Small molecule 50 mg —

Indications

gastroesophageal reflux disease